NDAORALTABLETPriority Review
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIJOICE (alpelisib) is an oral small-molecule PI3K inhibitor approved in 2022 for multiple oncology and rare genetic indications. It treats PIK3CA-driven cancers including breast cancer, ovarian cancer, endometrial cancer, and rare conditions like PIK3CA-related overgrowth spectrum and lymphatic malformations. The drug works by selectively inhibiting phosphatidylinositol 3-kinase (PI3K), blocking a key growth pathway in PIK3CA-mutated tumors.
$6MPart D
Peak10.8 years to LOEProduct is at peak lifecycle with modest Part D spending, indicating early commercialization phase with growth potential in rare disease and oncology segments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)
Started Oct 2025
104 enrolled
PIK3CA-related Overgrowth Spectrum (PROS)
24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs
Started Aug 2025
61 enrolled
Vascular AnomaliesVascular AnomalyTIE2/PIK3CA Pathway Driven Vascular Anomalies
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Started Sep 2024
51 enrolled
Endometroid Endometrial Cancer
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Started Nov 2023
232 enrolled
Lymphatic Malformations
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
Started Oct 2023
162 enrolled
Breast Cancer Stage IV
Worked on VIJOICE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.